Introduction {#s0001}
============

In April 2009 the World Health Organization declared an influenza pandemic caused by a novel H1N1 strain and appealed for accelerated vaccine development. In Europe, the resulting H1N1-vaccine coverage ranged between 0.4%--59% for the entire population, and 0.2%--74% for children.[@cit0001] Of the approximately 40 million persons vaccinated, over 30 million received *Pandemrix*™.[@cit0003]

An increase in narcolepsy cases was observed in Finland and Sweden toward the end of the 2009 pandemic.[@cit0004] Preliminary investigations suggested a temporal link to *Pandemrix*™, the only pandemic vaccine used in these 2 countries.[@cit0005] This led to numerous observational studies at country level, and a large multi-country case-control study in Europe ([**Table 1**](#t0001){ref-type="table"}). The relative risk estimates of the association between *Pandemrix*™ and narcolepsy ranged in children from 1.5--25.0 with confidence intervals (CIs) from 0.3--48.5, and in adults from 1.1--18.8, with CIs from 0.6--207.4 ([**Fig. 1**](#f0001){ref-type="fig"}). Figure 1.Risk estimates and 95% confidence intervals for *Pandemrix*™ vaccination and narcolepsy. Table 1.Summary of the design of 12 publically available studies assessing an association between pandemic AS03-adjuvanted H1N1 vaccination and narcolepsy  PopulationCase ascertainmentVaccine ascertainmentStudyDesignGeographic origin (period)SizeAgeSourceValidationSourceCoverageMPA-registry cohort, Sweden[@cit0008]RC7 counties (2009--2011)5.8 MAllContact with hospitals and sleep labs, spontaneous reportsNo expert reviewRegional vaccination registries60%MPA case-inventory, Sweden[@cit0005]RCNationwide (2009--2010) AllRegisters on hospitalisation and specialist careBy 2 experts in neurology/sleep disordersRegional vaccination registries60%Stockholm county cohort, Sweden[@cit0016]RCStockholm county (1998--2010)2 M\< 20 (for narcolepsy)Hospital registers, child rehabilitation, neurophysiology centersNo expert reviewLocal vaccination registry (Vaccinera)52.6%Western Sweden cohort[@cit0011]RCWestern Swedish health care region (2000--2010)0.4 M2--17 yrsNational and local hospital registers, register 3 specialized centersNo expert reviewUnclear Finnish childhood cohort[@cit0024]RCNationwide (2009--2010)0.9 M4--19 yrsNational hospital registersBy 2 narcolepsy experts. Discrepancies adjudicated by a narcolepsy expert panelElectronic primary health care databases75%Finnish adult cohort[@cit0025]RCNationwide (2009--2011)3.3 MAdultsNational hospital registers + direct contact pediatric neurologistsBy 2 narcolepsy experts. Discrepancies adjudicated by a narcolepsy expert panelElectronic primary health care databases48%Finnish case series[@cit0010]EcoNationwide (2002--2010) AllNational care register + direct contact health care professionalsBy 5 experts in neurology/sleep disordersVaccine certificates Irish cohort[@cit0026]RCNationwide (2009--2010)4.2 M4--19 yrs, ≥ 20 yrsDirect contact sleep and pediatric neurology centersBy an adult and pediatric neurologistReimbursement database and mass vaccination database22.5%English case-coverage[@cit0009]CCoNationwide (2008--2011)9.1 M4--18 yrsDirect contact sleep centersBy 3 narcolepsy expertsGP questionnaires1.9%[^\*^](#t1fn0002){ref-type="fn"}French case-control[@cit0013]CCNationwide (2009--2011)65 MAllDirect contact sleep centersBy 2 narcolepsy expertsTelephone interviews6.3%[^\*\*^](#t1fn0003){ref-type="fn"}VAESCO EU multi-country[@cit0003] Denmark, France, Italy, the Netherlands, Norway & UK: non-signaling + Sweden & FinlandCCNationwide or regional, (April 2009-June 2010)30 MAllVaried by country - registers, direct contact with sleep centersCountry dependentVariety of methodsVery low to highNorwegian cohort[@cit0027]RCNationwide (120 weeks from 2009 onwards)1 M\<20 yrsMedical institutions and practitionersBy a pediatrician and expert in sleep disordersNational vaccination register50%[^1][^2][^3]

When faced with such a safety signal, vaccine manufacturers will typically rely upon internal and external expertise to critically assess any studies that may influence the benefit-risk profile of the marketed product. As epidemiologists employed or sub-contracted by the manufacturer, the authors have identified a number of potential pitfalls that we believe have not necessarily been highlighted or discussed in detail in the published studies describing risk estimates of narcolepsy following vaccination with *Pandemrix*™. Our intent is to flag those potential pitfalls with an eye to future research into similar vaccine safety signals for rare or complex outcomes such as neurological/immune-mediated diseases. The objective of this review is therefore not to endorse or refute the observed association.

What are the Limitations of These Studies? {#s0002}
==========================================

Kleinbaum et al[@cit0007] distinguish 3 major sources of error in epidemiological research: information bias (the main concerns here being ascertainment bias and recall bias), selection bias and confounding. In the studies presented here, all of these sources of errors might have occurred to varying degrees ([**Table 2**](#t0002){ref-type="table"}). Table 2.Summary of main potential sources of errorStudyWeaknessesPossible source of error[@cit0021]MPA-registry cohort[@cit0008]No validation of casesAscertainment bias Unclear models and adjustmentsConfounding Clear degree of residual bias presentConfounding Role media attention not addressedAscertainment biasMPA case-inventory[@cit0005]Inclusion of spontaneous reportsSelection bias Blinding undefinedAscertainment bias Extrapolation of regional vaccination coverage dataConfounding Unclear models and adjustmentsConfoundingStockholm county cohort[@cit0016]Blinding undefinedAscertainment bias No validation of casesAscertainment bias Low powerConfounding Role media attention not addressedAscertainment biasWestern Sweden cohort[@cit0011]Unclear index dateInformation bias Uncertain validation of casesAscertainment bias Historical comparatorConfounding Unclear source for vaccination historyRecall biasFinnish childhood cohort[@cit0024]Potential impact of medical/media attentionAscertainment bias No control for potential confoundersConfounding Blinding undefinedAscertainment biasFinnish adult cohort[@cit0025]Potential impact of medical/media attentionInformation bias Uncertain validation of vaccinationInformation bias No adjustment for confoundersConfounding Blinding undefinedInformation biasFinnish case series[@cit0010]Ecological comparison of incidence ratesConfounding Unclear source of symptom onsetRecall bias Blinding undefinedAscertainment bias Unclear role of testing as part of the studyAscertainment biasIrish cohort[@cit0026]Case findings through direct contacts with potential bias toward inclusion vaccinated casesAscertainment bias Vaccination information potentially incompleteInformation bias Role media attention uncertainAscertainment bias No control for other confounders such as risk statusConfoundingEnglish case-coverage[@cit0009]Case findings through direct contacts with potential bias toward inclusion vaccinated casesAscertainment bias Low Vaccination coverageConfounding Comparability source cases and controls uncertainSelection bias Study period includes period high media attentionAscertainment biasFrench case-control[@cit0013]Participation biasSelection bias Potential bias toward inclusion vaccinated casesInformation bias High proportion of HCP among controlsSelection bias Vaccination status ascertained through interviewsRecall bias Blinding undefinedAscertainment biasVAESCO EU multi-country[@cit0003]Heterogeneity in methodsSelection bias Low vaccination coverageConfounding Blinding not defined for some countriesAscertainment bias Recruitment via direct contact with sleep centersSelection bias Vaccination status ascertained through interviewsRecall bias Limited adjustment for confoundersConfoundingNorwegian cohort[@cit0027]Incomplete capture vaccine registerInformation bias Potential bias toward inclusion vaccinated casesAscertainment bias Self-reported recall onset symptomsRecall bias Blinding undefinedAscertainment bias No control for potential confoundersConfounding[^4]

Ascertainment bias {#s0002-0001}
------------------

Ascertainment bias would have occurred if narcolepsy cases were more likely to be classified as cases if vaccinated. Such bias could have arisen at each step in the progression from symptoms to diagnosis (seeking care, being referred, undergoing sleep tests, and finally being diagnosed).

Vaccinated patients may have been more likely to seek care earlier if they were aware of the reported association between *Pandemrix*™ and narcolepsy, such as through media attention. Data from several studies suggest that biased healthcare seeking behavior occurred. In the Swedish MPA-registry study for example, a decrease in the risk estimate was reported when analyses included additional cases from a more recent registry release (RR of 4.2 versus 2.9 after an additional year of follow-up).[@cit0008] This decrease was a likely consequence of more unvaccinated cases being diagnosed and captured in the updated registers. Likewise, in the English case-coverage study, a large increase in the number of unvaccinated cases was seen when the study period was extended, compared to a minimal change in the number of vaccinated cases. This reduced the risk estimate from 22.2 to 11.0.[@cit0009]

The referral pattern of primary healthcare providers may have been influenced by heightened disease awareness and knowledge of the vaccination status of the presenting patients. This would result in a shorter time interval from symptom onset to diagnosis among the vaccinated compared to the unvaccinated. Such difference was observed in most studies, with the time-to-diagnosis up to 5--6 times shorter among the vaccinated in the Western Sweden cohort and Finnish case-series.[@cit0010] The shortened time-to-diagnosis could also be explained by a more severe clinical presentation in vaccinated patients. However, the comparison of other disease characteristics, such as hypocretin levels or sleep latency test results, does not support the notion of a different clinical presentation among vaccinated patients.[@cit0005]

At the referral center, patients may have been managed differentially based on vaccination status. Illustrative for this is the difference in rates of hypocretin testing between vaccinated (59%) and unvaccinated (only 17%) cases, as reported in the French study.[@cit0013] Finally, the classification of a patient (at the referral center) as having narcolepsy could be differential based on vaccination status. Evidence of such differential misclassification can be assessed in studies where experts reviewed the reported cases. A differential misclassification would lead to more vaccinated patients being falsely labeled positive at the referral center and thus a relatively high vaccination rate among the cases classified as non-cases by expert review. In the MPA case-inventory study, the proportion of vaccinated among the rejected cases was 78% (14/18)[@cit0005] compared to a national coverage of 63% in the same age group.[@cit0014] Differential validation of vaccinated cases is avoidable by blinding the validating experts to vaccination status. Such blinding did not occur or was not explicitly reported in most studies ([**Table 2**](#t0002){ref-type="table"}).

Recall bias {#s0002-0002}
-----------

The onset of symptoms relied on patient recall in many studies and was thus prone to recall bias. Given the media attention that occurred before most studies took place, it is plausible that onset of symptoms was preferentially linked to the onset of the pandemic and the associated vaccination campaigns. While recall bias is difficult to prove including in the studies considered, its existence in other vaccine safety studies has been previously highlighted.[@cit0015]

Selection bias {#s0002-0003}
--------------

Selection bias resulting in falsely increased risk estimates would have occurred if vaccinated cases or unvaccinated controls were preferentially enrolled. In the MPA case-inventory study,[@cit0016] cases reported to the spontaneous reporting system were included. These cases were by definition vaccinated, and their inclusion may have skewed the results toward falsely inflated risk estimates in this group. The French case-control study relied upon a selection of controls that differed from cases in some important aspects, such as the proportion of healthcare professionals, a group targeted for vaccination.[@cit0013] In the English case-coverage study, the controls were drawn from an independent subset of the general population, with limited information allowing no matching and minimal adjustment for potential confounders.[@cit0009]

Confounding {#s0002-0004}
-----------

The most important confounders in the studies of *Pandemrix*™ and narcolepsy are confounding by indication and confounding by natural H1N1 infection. Confounding by indication would have occurred if the indication for which H1N1 vaccination was recommended also carried an increased risk to develop narcolepsy. Although influenza risk factors are not known to be linked with higher narcolepsy risk, an elevated (non-significant) odds ratio of 3.53 for H1N1 vaccination in the first 45 d of the campaign was found for subjects with prevalent narcolepsy in the Stockholm county-cohort study, suggesting confounding by indication.[@cit0016] In the English case-coverage study, matching by risk group reduced the odds ratios nearly two-fold, a further illustration that would support potential confounding.[@cit0009] Few other studies had the possibility to adjust for this confounder.

The timing of vaccination campaigns and epidemics had a near-perfect match in most European countries. Natural infection could have acted as a confounder if individuals infected by H1N1 virus were more prone to seek care and be targeted for vaccination. The observed association could thus incorrectly be attributed to the vaccine instead of the viral infection itself. The strong temporal correlation between the incidence of narcolepsy and the H1N1 pandemic wave observed in China suggests such a confounding effect is plausible.[@cit0017] A recent attempt to test for past H1N1 infection among vaccinated narcolepsy cases did not find a higher exposure rate among narcolepsy cases.[@cit0018] However, the approach used to establish evidence of past infection is not validated and debatable.[@cit0019]

Additional potential sources of confounding are numerous and include healthcare seeking behavior, socio-economic status, ethnic background and frailty in general. The MPA-registry cohort study showed that the vaccinated cohort had a higher number of ambulatory care visits and hospitalisations prior to the study start, illustrating the potential confounding by healthcare seeking behavior.[@cit0008] In the Stockholm county cohort study, adjustment for healthcare utilization decreased the risk estimates for nearly all outcomes, including narcolepsy.[@cit0016] The MPA-registry study showed that vaccinees had a higher income level and were more likely to be born in Nordic countries.[@cit0008] The link between these determinants and the risk of having/being diagnosed with narcolepsy is obvious for some parameters (Nordic origin is associated with higher levels of the HLA allele carriage[@cit0020]) and cannot be excluded for the others.

What Could Have Been Done Differently (Or Can Still be Done)? {#s0003}
=============================================================

Most studies were pragmatic in nature, taking advantage of pre-existing datasets such as registries, and combining data thereof with vaccination data from different sources into a cohort or case-coverage design. As a result, there was no systematic collection of comparable data across the comparator groups and therefore minimal opportunity to control for confounding factors. While these studies may have been the most efficient and rapid means to analyze and report the available information, few of their limitations were thoroughly addressed. Beyond varying index dates and observation period, no systematic assessment of other potential biases such as those listed above was performed and certainly no integrated analyses of all these biases combined were performed. Performing such analyses is increasingly recognized as good practice in pharmaco-epidemiological research,[@cit0021] particularly in studies with such far-reaching public health implications.

Alternative methods to analyze the data could also have been considered, such as the self-controlled case series (SCCS) or case-negative designs. The SCCS implicitly controls for fixed confounders such as healthcare seeking behavior and confounding by indication, but it cannot control for time-dependent covariates such as infection and is suboptimal for assessment of chronic onset disease. In the English study, the risk estimates from the SCCS analyses were about ten-fold lower compared to the analyses from the case-coverage study, and were not significant unless the study period was increased.[@cit0009] Possibly the most appropriate design may be a test-negative case-control design in which vaccination rates would be compared between cases validated as narcoleptic to subjects suspected for narcolepsy but confirmed not to be narcoleptic after assessment by an expert. This approach would ensure that cases and controls are drawn from a population with comparable propensity to seek care, including vaccination, or be referred for diagnosis. This design has been extensively used in influenza vaccine effectiveness studies using similar arguments.[@cit0022]

Summary {#s0003-0001}
=======

In summary, there are limitations to the observational studies of the association between *Pandemrix™* and narcolepsy, putting into question whether the relative risks observed in them reflect the true risk associated with *Pandemrix™* vaccination. No systematic assessment was done of the potential impact of all potential biases or confounders. The consistency of the findings, as well as the strength of the association have been repeatedly mentioned as arguments toward a true association.[@cit0023] But consistency in bias and confounding may also lead to consistently false positive results. While we acknowledge that a single confounder or bias may not explain the risk estimates observed, the combined effect of several confounding factors should not be underestimated. We advocate that researchers engage in a collaborative effort involving all stakeholders (vaccine manufacturers, academia, public health and regulators) to examine the possibility of reanalysing the data using designs that may be less prone to bias, and perform more systematic sensitivity analyses to assess the potential role of these biases. Whether the observed strength of the association will still stand after the use of more appropriate designs and adjustment is an open question. As a minimum, better estimates of the attributable risk will allow for a more informed assessment of benefit-risk.

Key messages {#s0003-0002}
------------

Epidemiological studies suggest an association between *Pandemrix™* and narcolepsy. Whether this temporal association can also be interpreted as a causal association is less clear, and should be considered with caution.The important methodological concerns that apply to a certain extent to all available epidemiological studies are various ascertainment biases, recall bias, selection bias, confounding by indication, and the impossibility to distinguish between exposure to the vaccine and exposure to the virus due to their close temporal proximity.For each of these potential errors there are indications that they may have affected the risk estimates. A systematic assessment of the potential combined impact of these biases and confounders is needed for informed benefit/risk decision making.Alternative designs such as the test-negative case-control design can be expected to account for several of the biases and confounders observed.
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[^1]: MPA = Medical products Agency, M = millions, RC = retrospective cohort. CS = case series, CC = case control, CCo = case coverage, Eco = ecological study,

[^2]: 37% in the 2--15 y old risk group and includes some use of unadjuvanted vaccines in pregnant women and young infants,

[^3]: mostly 9 y of age and older.

[^4]: HCP = healthcare personnel.
